REVIVA PHARMACEUTICALS HOLDINGS, INC.

(RVPH)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Reviva Pharmaceuticals Holdings, Inc. Receives FDA May Proceed Letter for Pivotal Phase 3 Clinical Trial and Long-Term Safety Trial Evaluating Brilaroxazine for the Treatment of Schizophrenia

01/10/2022 | 06:00am EDT

Reviva Pharmaceuticals Holdings, Inc. announced the U.S. Food and Drug Administration (FDA) has notified the Company that it may proceed with Phase 3 clinical investigation of its lead candidate, brilaroxazine, a novel serotonin and dopamine receptor modulator for the treatment of schizophrenia. Schizophrenia is a complex and debilitating neuropsychiatric disorder that affects 1% of the world’s population, and approximately 3.5 million people in the United States alone. Characterized by multiple symptoms, patients with schizophrenia often suffer from cognitive impairment, delusions, hallucinations and disorganized speech or behavior. Despite its high prevalence, there are no therapies that adequately address the complex mix of positive and negative symptoms, mood, and cognitive impairment associated with schizophrenia. Limitations of current treatments include suboptimal efficacy, poor tolerability and low patient adherence rates.


© S&P Capital IQ 2022
All news about REVIVA PHARMACEUTICALS HOLDINGS, INC.
05/17Reviva Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
AQ
05/16REVIVA PHARMACEUTICALS HOLDINGS, INC : Results of Operations and Financial Condition, Regu..
AQ
05/16REVIVA PHARMACEUTICALS HOLDINGS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIA..
AQ
05/16Reviva Pharmaceuticals Holdings, Inc. Reports Earnings Results for the First Quarter En..
CI
05/16Reviva Pharmaceuticals Holdings, Inc. Reports First Quarter 2022 Financial Results and ..
AQ
05/03Reviva Pharmaceuticals Announces Update on RECOVER, a Pivotal Phase 3 Global Study Eval..
AQ
05/03Reviva Pharmaceuticals Holdings, Inc. Announces Update on RECOVER, a Pivotal Phase 3 Gl..
CI
04/26Reviva Pharmaceuticals to Host Key Opinion Leader Webinar on Brilaroxazine for Schizoph..
AQ
03/24Reviva Pharmaceuticals Holdings, Inc. Interview to Air on Bloomberg U.S. on the RedChip..
AQ
03/22Reviva Pharmaceuticals Holdings, Inc. to Participate at the Maxim Virtual Growth Confer..
AQ
More news
Analyst Recommendations on REVIVA PHARMACEUTICALS HOLDINGS, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -25,8 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,35x
Yield 2022 -
Capitalization 26,5 M 26,5 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 -
Nbr of Employees 5
Free-Float 64,4%
Chart REVIVA PHARMACEUTICALS HOLDINGS, INC.
Duration : Period :
Reviva Pharmaceuticals Holdings, Inc. Technical Analysis Chart | RVPH | US76152G1004 | MarketScreener
Technical analysis trends REVIVA PHARMACEUTICALS HOLDINGS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Last Close Price 1,75 $
Average target price 10,33 $
Spread / Average Target 490%
EPS Revisions
Managers and Directors
Laxminarayan Bhat President, Chief Executive Officer & Director
Narayan Prabhu Chief Financial Officer
Parag Phoolchand Saxena Chairman
Marcus Cantillon Chief Medical Officer
Richard A. Margolin Independent Director
Sector and Competitors
1st jan.Capi. (M$)
REVIVA PHARMACEUTICALS HOLDINGS, INC.-39.45%26
MODERNA, INC.-46.35%54 195
LONZA GROUP AG-27.84%41 796
IQVIA HOLDINGS INC.-28.46%38 202
SEAGEN INC.-9.68%25 704
ICON PUBLIC LIMITED COMPANY-30.22%17 567